orthopedic surgery

What Will It Take to Move Procedures to the Office?

Orthopedic surgeons and companies focused on sports medicine and trauma seek to move more low-risk procedures into offices.

According to our estimates, just under 50 companies accounted for more than 85% of all orthopedic revenue in 2023.

Orthopedics’ Top Tier to Expand in 2024

According to our estimates, just under 50 companies accounted for more than 85% of all orthopedic revenue in 2023.

Funding announcements came from familiar names and supported well-backed markets like spine and enabling technology.

10 Orthopedic Companies Close New Funding Rounds in 1Q24

Funding announcements came from familiar names and supported well-backed markets like spine and enabling technology.

Orthoflash®
Corin Apollo Robotic-Assisted Surgical Platform
Corin Gains CE Mark Approval for Apollo Robotic-Assisted Surgical Platform

Corin will commercialize the Apollo robotic-assisted surgical platform and the ApolloKnee procedure throughout the European Union.

,
SAIL Fusion BowTie Sacroiliac Fusion System
SAIL Fusion Gains FDA 510(k) for BowTie Sacroiliac Fusion

BowTie is reported to be the only SI fusion device to incorporate intra-articular and transfixing components.

,
Captiva Spine WatchTower Navigation
Study Affirms Effectiveness of WatchTower Spine Navigation

Captiva Spine’s WatchTower Navigation registers a pre-op CT scan with 2D C-arm imaging, using an algorithm to provide real-time 3D navigation during surgery.

,
Exactech Newton Soft Tissue Balancing Technology
Exactech Granted Patents for Newton Soft Tissue Balancing Technology

Newton Knee works with ExactechGPS to provide dynamic soft tissue analytics, pre-resection operative insights and full-range personalized planning.

,
Hyalex Orthopaedics is running the prospective, multi-center, single-arm studies in the U.S. and Europe, with sites for both studies having already enrolled and treated patients.
Treatment of First Patients with HYALEX Knee Cartilage System

Hyalex Orthopaedics is running the prospective, multi-center, single-arm studies in the U.S. and Europe, with sites for both studies having already enrolled and treated patients.

,
Competitive Landscape
Industry Voices

Contact Us

0